Investors alleged that drugmaker Pfizer violated federal securities laws by making false, misleading or incomplete statements regarding the cardiovascular risks of Celebrex and Bextra. Seeger Weiss helped secure a $486 million settlement on behalf of the investors.
Prior results do not guarantee or predict a similar outcome in any future matter.
Seeger Weiss attorneys Stephen A. Weiss and Justin M. Smigelsky have published an article titled “Sounding the Alarm” in the July 2025 issue of Trial Magazine, the publication of the American Association for Justice. The article examines strategies for protecting whistleblowers in False Claims Act cases, drawing from their representation in United States v. Stimwave […]
Seeger Weiss is proud to announce that the firm—alongside partners Christopher Seeger, David Buchanan, Ben Barnett, and Parvin Aminolroaya—has been recognized in the newly released Chambers 2025 USA Guide. This marks the fifth consecutive year that Seeger Weiss has been recognized by Chambers USA. For over three decades, Chambers has been a trusted authority in […]
We are proud to announce that ten Seeger Weiss attorneys have been selected to Lawdragon’s 2025 Leading Plaintiff Financial Lawyers guide list, which honors attorneys who represent plaintiffs in complex financial litigation. Congratulations to Parvin Aminolroaya, Christopher Ayers, Ben Barnett, David R. Buchanan, Steven Daroci, Shauna Itri, Jeremy Kasha, Jennifer Scullion, Christopher Seeger, and Stephen […]
Seeger Weiss LLP, led by founding partner Christopher A. Seeger, has made a $500,000 donation to the Bolch Judicial Institute at Duke Law School to establish The Seeger Weiss/Daniel Anderl Memorial Fund, which will provide long-term, flexible funding for the Institute to support two critical areas of the legal system: defending judicial independence and advancing […]
Seeger Weiss attorneys played a key role in this case, helping negotiate an efficient and positive settlement for investor plaintiffs. Partner Dave Buchanan developed a slate of experts to overcome Pfizer’s early science challenges to the case. Founding partner Chris Seeger led the plaintiff’s presentation and examinations during the seven-day Daubert hearing.
Following pre-trial motion practice and ensuing appeals, Pfizer settled the case, resulting in a $486 million cash settlement fund for the class of aggrieved investors.
Pfizer allegedly misled shareholders about risks associated with two prescription medications: arthritis medication, Celebrex, and painkiller, Bextra. Evidence indicated that Pfizer recognized the potential cardiovascular risks of these medications but deliberately concealed these risks from shareholders. Plaintiffs alleged that these omissions violated federal securities laws, defrauding a class of investors.
Seeger Weiss attorneys Stephen A. Weiss and Justin M. Smigelsky have published an article titled “Sounding the Alarm” in the July 2025 issue of Trial Magazine, the publication of the American Association for Justice. The article examines strategies for protecting whistleblowers in False Claims Act cases, drawing from their representation in United States v. Stimwave […]
Seeger Weiss is proud to announce that the firm—alongside partners Christopher Seeger, David Buchanan, Ben Barnett, and Parvin Aminolroaya—has been recognized in the newly released Chambers 2025 USA Guide. This marks the fifth consecutive year that Seeger Weiss has been recognized by Chambers USA. For over three decades, Chambers has been a trusted authority in […]
We are proud to announce that ten Seeger Weiss attorneys have been selected to Lawdragon’s 2025 Leading Plaintiff Financial Lawyers guide list, which honors attorneys who represent plaintiffs in complex financial litigation. Congratulations to Parvin Aminolroaya, Christopher Ayers, Ben Barnett, David R. Buchanan, Steven Daroci, Shauna Itri, Jeremy Kasha, Jennifer Scullion, Christopher Seeger, and Stephen […]
Seeger Weiss LLP, led by founding partner Christopher A. Seeger, has made a $500,000 donation to the Bolch Judicial Institute at Duke Law School to establish The Seeger Weiss/Daniel Anderl Memorial Fund, which will provide long-term, flexible funding for the Institute to support two critical areas of the legal system: defending judicial independence and advancing […]